IBSENDA Trademark

Trademark Overview


On Monday, December 15, 2014, a trademark application was filed for IBSENDA with the United States Patent and Trademark Office. The USPTO has given the IBSENDA trademark a serial number of 86480995. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 7, 2016. This trademark is owned by Furiex Pharmaceuticals, Inc.. The IBSENDA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, Transdermal, Injectable and Intravaginal Contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals...
ibsenda

General Information


Serial Number86480995
Word MarkIBSENDA
Filing DateMonday, December 15, 2014
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 7, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 9, 2015

Trademark Statements


Goods and ServicesOral, Transdermal, Injectable and Intravaginal Contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics, Antifungals, Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 19, 2014
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameFURIEX PHARMACEUTICALS, LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressPARSIPPANY, NJ 07054

Party NameFuriex Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameFuriex Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Wednesday, March 9, 2016AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, March 7, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, March 7, 2016ABANDONMENT - NO USE STATEMENT FILED
Tuesday, August 4, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 9, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 9, 2015PUBLISHED FOR OPPOSITION
Wednesday, May 20, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 6, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, May 6, 2015ASSIGNED TO LIE
Tuesday, April 14, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 8, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 8, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 8, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 27, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 27, 2015NON-FINAL ACTION E-MAILED
Friday, March 27, 2015NON-FINAL ACTION WRITTEN
Wednesday, March 25, 2015ASSIGNED TO EXAMINER
Friday, December 19, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, December 18, 2014NEW APPLICATION ENTERED IN TRAM